abs325.txt	randomized	trials	outside	the	u	s		have	found	non-inferior	survival	forneoadjuvant	chemotherapy	(nact)	versus	primary	debulking	surgery	(pds)	foradvanced	ovarian	cancer	(aoc)		however		these	trials	reported	lower	overallsurvival	and	lower	rates	of	optimal	debulking	than	u	s		studies		leading	toquestions	about	generalizability	to	u	s		practice		where	aggressive	debulking	ismore	common		consequently		comparative	effectiveness	in	the	u	s		remainscontroversial		we	reviewed	u	s		comparative	effectiveness	studies	of	nact	versuspds	for	aoc		here	we	describe	methodological	challenges		compare	results	totrials	outside	the	u	s			and	make	suggestions	for	future	research		we	identifiedu	s		studies	published	in	2010	or	later	that	evaluated	the	comparativeeffectiveness	of	nact	versus	pds	on	survival	in	aoc	through	a	pubmed	search		twoindependent	reviewers	abstracted	data	from	eligible	articles		nine	of	230articles	were	eligible	for	review		methodological	challenges	included	unmeasuredconfounders		heterogeneous	treatment	effects		treatment	variations	over	time		andinconsistent	measurement	of	treatment	and	survival		whereas	some	limitations	wereunavoidable		several	limitations	noted	across	studies	were	avoidable		includingconditioning	on	mediating	factors	and	immortal	time	introduced	by	measuringsurvival	beginning	from	diagnosis		without	trials	in	the	u	s			non-randomizedstudies	are	an	important	source	of	evidence	for	the	ideal	treatment	for	aoc	however		several	methodological	challenges	exist	when	assessing	the	comparativeeffectiveness	of	nact	versus	pds	in	a	non-randomized	setting		futureobservational	studies	must	ensure	that	treatment	is	consistent	throughout	thestudy	period	and	that	treatment	groups	are	comparable		rapidly-evolving	oncologydata	networks	may	allow	for	identification	of	treatment	intent	and	otherimportant	confounders	
